| 1 |
Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer[J]. Lancet, 2019, 394(10207): 1467-1480.
|
| 2 |
Lu SH, Tsai WS, Chang YH, et al . Identifying cancer origin using circulating tumor cells[J]. Cancer Biol Ther, 2016, 17(4): 430-438.
|
| 3 |
Pantel K, Speicher MR. The biology of circulating tumor cells[J]. Oncogene, 2016, 35(10): 1216-1224.
|
| 4 |
Tsai W, Chen J, Shao H, et al. Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients[J]. Sci Rep, 2016, 14(6): 24517.
|
| 5 |
Chen J, Ye C, Dong J, et al. Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer[J]. Transl Med, 2020, 18(1): 59.
|
| 6 |
Montgomery B, Plymate S. Clinical acumen versus angrogen receptor variant 7 circulating tumor cells in decision-making for men with advanced prostate cancer[J]. Eur Urol, 2019, 77(2): 178-179.
|
| 7 |
Morrison GJ, Gunha AT, Jojo N, et al. Cancer transcriptomic profiling from rapidly enriched circulating tumor cells[J]. Int J Cancer, 2020, 146(10): 2845-2854.
|
| 8 |
Magni E, Botteri E, Ravenda PS, et al. Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery[J]. Int J Colorectal Dis, 2014, 29(9): 1053-1059.
|
| 9 |
Sun W, Huang T, Li G, et al. The advantage of circulating tumor cells over serum carcinoembryonic antigen for predicting treatment responses in rectal cancer[J]. Future Oncol, 2013, 9(10): 1489-1500.
|
| 10 |
Sun W, Li G, Wan J, et al. Circulating tumor cells: A promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy[J]. Oncotarget, 2016, 7(43): 69507-69517.
|
| 11 |
Sun W, Jia C, Huang T, et al. High-performance size-based microdevice for the detection of circulating tumor cells from peripheral blood in rectal cancer patients[J]. PLoS One, 2013, 8(9): e75865.
|
| 12 |
Troncarelli Flores BC, Souza E Silva V, Ali Abdallah E, et al. Molecular and kinetic analyses of circulating tumor cells as predictive markers of treatment response in locally advanced rectal cancer patients[J]. Cells, 2019, 8(7): 641.
|
| 13 |
Diaz LAJr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA[J]. J Clin Oncol, 2014, 20, 32(6): 579586.
|
| 14 |
Warton K, Samimi G. Methylation of cell-free circulating DNA in the diagnosis of cancer[J]. Front Mol Biosci, 2015, (2): 13.
|
| 15 |
Mokarram P, Rismanchi M, Alizadeh NM, et al. Microsatellite instability typing in serum and tissue of patients with colorectal cancer: comparing real time PCR with hybridization probe and high-performance liquid chromatography[J]. Mol Biol Rep, 2014, 41(5): 2835-2844.
|
| 16 |
Sun W, Sun Y, Zhu M, et al. The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients[J]. Oncol Rep, 2014, 31(3): 1466-1472.
|
| 17 |
Agostini M, Pucciarelli S, Enzo MV, et al. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy[J]. Ann Surg Oncol, 2011, 18(9): 2461-2468.
|
| 18 |
Sideris M, Moorhead J, Diaz-Cano S, et al. KRAS mutant status may be associated with distant recurrence in early-stage rectal cancer[J]. Anticancer Res, 2017, 37: 1349-1357.
|
| 19 |
Shalaby SM, EI-Shal AS, Abdelaziz LA, et al. Promoter methylation and expression of DNA repair genes MGMT and ERCC1 in tissue and blood of rectal cancer patients[J]. Gene, 2018, 644: 66-73.
|
| 20 |
Zou D, Day R, Cocadiz JA, et al. Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer[J]. Carcinogenesis[J]. 2020, 41(11): 1507-1517.
|
| 21 |
Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci USA, 2008, 105(30): 10513-10518.
|
| 22 |
Azizian A, Kramer F, Jo P, et al. Preoperative prediction of lymph node status by circulating mir-18b and mir-20a during chemoradiotherapy in patients with rectal cancer[J]. World J Surg, 2015, 39(9): 2329-2335.
|
| 23 |
D'Angelo E, Fassan M, Maretto I, et al. Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma[J]. Oncotarget, 2016, 7(19): 28647-28657.
|
| 24 |
Yu J, Li N, Wang X, et al. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer[J]. Oncotarget, 2016, 7(39): 64233-64243.
|
| 25 |
Dayde D, Tanaka I, Jain R, et al. Predictive and prognostic molecular biomarkers for response to neoadjuvant chemoradiation in rectal cancer[J]. Int J Mol Sci, 2017, 18(3): E573.
|
| 26 |
Lee JH, Hyun JH, Kim DY, et al. The role of fibrinogen as a predictor in preoperative chemoradiation for rectal cancer[J]. Ann Surg Oncol, 2015, 22(1): 209-215.
|
| 27 |
Han YD, Kim WR, Park SW, et al. Predictors of pathologic complete response in rectal cancer patients undergoing total mesorectal excision after preoperative chemoradiation[J]. Medicine (Baltimore), 2015, 94(45): e1971.
|
| 28 |
Buijsen J, van Stiphout RG, Menheere PP, et al. Blood biomarkers are helpful in the prediction of response to chemoradiation in rectal cancer: a prospective, hypothesis driven study on patients with locally advanced rectal cancer [J]. Radiother Oncol, 2014, 111(2): 237-242.
|
| 29 |
Agatea L, Crotti S, Ragazzi E, et al. Peptide patterns as discriminating biomarkers in plasma of patients with familial adenomatous polyposis[J]. Clin Colorectal Cancer, 2016, 15(3): e75-e92.
|
| 30 |
Giessen C, Nagel D, Glas M, et al. Evaluation of preoperative serum markers for individual patient prognosis in stage Ⅰ-Ⅲ rectal cancer[J]. Tumour Biol, 2014, 35(10): 10237-10248.
|
| 31 |
Hu H, Huang J, Lan P, et al. CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial[J]. BMC Cancer, 2018, 18(1): 1145.
|
| 32 |
Benej M, Pastorekova S, Pastorek J. Carbonic anhydrase Ⅸ: regulation and role in cancer[J]. Subcel Biochem, 2014, 75: 199-219.
|
| 33 |
Hektoen HH, Flatmark K, Andersson Y, et al. Early increase in circulating carbonic anhydrase Ⅸ during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer[J]. BMC Cancer, 2015, 15: 543.
|
| 34 |
Crotti S, Piccoli M, Rizzolio F, et al. Extracellular matrix and colorectal cancer: how surrounding microenvironment affects cancer cell behavior?[J]. J Cell Physiol, 2017, 232(5): 967-975.
|
| 35 |
Aldulaymi B, Christensen IJ, Sölétormos G, et al. Chemoradiation-induced changes in serum CEA and plasma TIMP-1 in patients with locally advanced rectal cancer[J]. Anticancer Res, 2010, 30(11): 4755-4759.
|
| 36 |
Yoon HI, Koom WS, Kim YB, et al. Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzymelinked immunosorbent assays (ELISAs) for biomarkers[J]. J Cancer Res Clin Oncol, 2014, 140(3): 399-409.
|
| 37 |
Roayaei M, Emami H, Adeli P, et al. Predictive value of tissue inhibitor of metalloproteinases-1 and carcinoembryonic antigen plasma levels in response to chemotherapy in patients with metastatic colorectal cancer[J]. J Res Med Sci, 2014, 19(12): 1129-1133.
|
| 38 |
Dreyer SB, AGMTPowell, McSorley ST, et al. The pretreatment systemic inflammatory response is an important determinant of poor pathologic response for patients undergoing neoadjuvant therapy for rectal cancer[J]. Ann Surg Oncol, 2017, 24(5): 1295-1303.
|
| 39 |
Ide S, Toiyama Y, Okugawa Y, et al. Clinical significance of creactive protein-to-albumin ratio with rectal cancer patient undergoing chemoradiotherapy followed by surgery[J]. Anticancer Res, 2017, 37(10): 5797-5804.
|
| 40 |
Erben P, Ströbel P, Horisberger K, et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab based chemoradiotherapy in locally advanced rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4): 1032-1038.
|
| 41 |
Crotti S, Enzo MV, Bedin C, et al. Clinical predictive circulating peptides in rectal cancer patients treated with neoadjuvant chemoradiotherapy[J]. J Cell Physiol, 2015, 230(8): 1822-1828.
|
| 42 |
Lim SH, Chua W, Henderson C, et al. Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. Crit Rev Oncol Hematol, 2015, 96: 67-80.
|
| 43 |
Tada N. Changes in the plasma levels of cytokines/chemokines for predicting the response to chemoradiation therapy in rectal cancer patients[J]. Oncol Rep, 2013, 31: 163-471.
|
| 44 |
Caputo D, Caricato M, Coppola A, et al. Neutrophil to lymphocyte ratio (NLR) and derived neutrophil to lymphocyte ratio (d-NLR) predict non-responders and postoperative complications in patients undergoing radical surgery after neo-adjuvant radio-chemotherapy for rectal adenocarcinoma[J]. Cancer Investig, 2016, 34: 440-451.
|
| 45 |
Dong YW, Shi YQ, He LW, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in rectal cancer: A meta-analysis[J]. Oncotargets Ther, 2016, 9: 3127-3134.
|